RenovoRx Announces Orphan Drug Designation Granted for Treating Bile Duct Cancer
RenovoRx today announced the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for treating bile duct cancer—- also known as cholangiocarcinoma— with intra-arterial gemcitabine. The Company’s proprietary FDA cleared medical device system, RenovoCath®, employs a dual-balloon infusion catheter, enabling the Trans-Arterial Micro-Perfusion (TAMPTM) approach for targeted delivery of gemcitabine to the tumor site.
RenovoRx Announces Orphan Drug Designation Granted for Treating Bile Duct Cancer
RenovoRx, an innovator in targeted cancer therapy, today announced the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for treating bile duct cancer—- also known as cholangiocarcinoma— with intra-arterial gemcitabine. The Company’s proprietary FDA cleared medical device system, RenovoCath®, employs a dual-balloon infusion catheter, enabling the Trans-Arterial Micro-Perfusion (TAMPTM) approach for targeted delivery of gemcitabine to the tumor site.